Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Cardiology · Arrhythmogenic Cardiomyopathy

Treatment Options & The Standard of Care

At a Glance

The standard of care for Arrhythmogenic Cardiomyopathy (ACM) focuses on preventing sudden cardiac events and slowing disease progression. Key treatments include strict exercise restrictions, beta-blockers to reduce heart strain, and an ICD for high-risk patients.

The treatment for Arrhythmogenic Cardiomyopathy (ACM) focuses on three main goals: preventing sudden cardiac events, slowing the progression of heart muscle damage, and managing irregular heart rhythms (arrhythmias) [1][2]. Because ACM is a progressive disease, your treatment plan will likely evolve over time.

The Most Critical Medicine: Exercise Restriction

In many conditions, exercise is the best medicine. In ACM, the opposite is true. Vigorous physical activity is a primary driver of the disease [3][1].

  • Mechanical Strain: High-intensity movement physically pulls on the weakened heart cell connections (the desmosome), which accelerates the replacement of muscle with scar and fat [3][4].
  • What is Forbidden: Competitive sports, heavy weightlifting (the Valsalva maneuver causes sudden blood pressure spikes that strain the heart), CrossFit, sprinting, and endurance running [5][1].
  • What is Generally Allowed: Low-to-moderate intensity activities like leisurely walking, light yoga, or easy cycling [5][3].
  • The Heart Rate Zone: You must ask your doctor for a specific maximum heart rate limit. Many patients find it incredibly helpful to invest in a smartwatch or a chest-strap heart rate monitor to ensure they do not exceed their doctor-approved “safe zone” during daily activities [5][1].

Medications: Protecting the Heart

The standard pharmacological approach for ACM involves several types of medication:

  1. Beta-Blockers (e.g., Nadolol, Bisoprolol, Carvedilol): These are the cornerstone of ACM care [2][1]. They block the effects of adrenaline on the heart, reducing the triggers for dangerous rhythms and lessening the mechanical strain on the heart muscle [2][1].
  2. Antiarrhythmics (e.g., Sotalol, Flecainide, Amiodarone): If beta-blockers alone aren’t enough, doctors may add these to stabilize the electrical system [1][6].
    • A Note on Amiodarone: Because ACM patients are often young and may need medication for decades, it is vital to know that Amiodarone carries severe long-term side effects. If prescribed, it requires strict, ongoing monitoring of your thyroid, lungs, and liver [7][1].

Preventing Sudden Events: The ICD

An Implantable Cardioverter-Defibrillator (ICD) is a device that monitors your heart rhythm and delivers a life-saving shock to reset it if it detects a dangerous, fast rhythm [1]. Doctors use the 2019 ARVC Risk Model to calculate your 5-year risk and determine if you need one [8].

  • The Reality of an ICD: Getting an ICD does not involve open-heart surgery. It is typically a minor surgical procedure where a small device (about the size of a stopwatch) is placed just under the skin, usually below the collarbone or under the armpit (subcutaneous ICD). Thin wires (leads) are guided through a vein into the heart, or tunneled under the skin. Recovery is generally quick, though you will have temporary arm movement restrictions for a few weeks to allow the wires to settle [9][1].

Managing Heart Failure and Advanced Disease

Because ACM is a progressive disease, some patients—especially those with DSP or PLN mutations—may develop heart muscle weakness or heart failure over time [10][11].

  • Heart Failure Meds: Your doctor may prescribe medications to take the load off your heart, such as ACE inhibitors, ARBs, SGLT2 inhibitors, or diuretics (water pills) [1][2].
  • Advanced Options: In very advanced, end-stage cases where the heart is failing and no longer responding to medications or ablation, a heart transplant may become a necessary intervention. While rare, it is a definitive treatment for the structural damage of ACM [12][1].

Advanced Procedures: Catheter Ablation

If you continue to have frequent arrhythmias (ventricular tachycardia or VT) that medications cannot control, your doctor may suggest catheter ablation [13][1].

In this procedure, a specialist uses a thin tube to find the “short circuit” and applies energy to neutralize it [14].

  • Endocardial Ablation: Performed on the inside of the heart wall [13].
  • Epicardial Ablation: Performed on the outside of the heart wall. This is often necessary in ACM because the disease typically starts on the outer surface of the heart [13][15].

Ablation can significantly reduce irregular beats and ICD shocks, but it does not “cure” the underlying genetic condition [16][17].

Common questions in this guide

Can I exercise if I have arrhythmogenic cardiomyopathy?
Vigorous physical activity is restricted because mechanical strain can accelerate heart muscle damage. However, your doctor may allow low-to-moderate activities like leisurely walking or light yoga, provided you stay within a specifically approved safe heart rate zone.
What medications are used to treat ACM?
Beta-blockers are the cornerstone of ACM treatment because they reduce mechanical strain and help prevent dangerous heart rhythms. Your doctor may also prescribe antiarrhythmic drugs like sotalol or amiodarone, or heart failure medications if the disease progresses.
How do doctors decide if I need an ICD?
Cardiologists determine your need for an ICD by using the 2019 ARVC Risk Model to calculate your 5-year risk of a serious heart rhythm event. An ICD is a small device placed under the skin that monitors your heart and delivers a life-saving shock if a dangerous rhythm occurs.
What is catheter ablation for ACM?
Catheter ablation is a procedure used when medications cannot control irregular heartbeats. A specialist guides a thin tube to the heart and applies energy to neutralize the tissue causing the short circuit. For ACM, this is often done on the outside of the heart (epicardial ablation).

Get notified when new evidence is published on Inherited arrhythmogenic cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Sudden death related cardiomyopathies - Arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and exercise-induced cardiomyopathy.

    Goff ZD, Calkins H

    Progress in cardiovascular diseases 2019; (62(3)):217-226 doi:10.1016/j.pcad.2019.04.002.

    PMID: 31004608
  2. 2

    [Arrhythmogenic right ventricular cardiomyopathy : An update].

    Marchetti M, Pascale P, Muller O, Lu H

    Annales de cardiologie et d'angeiologie 2022; (71(4)):223-227 doi:10.1016/j.ancard.2022.08.006.

    PMID: 36089416
  3. 3

    Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

    Eberly L, Garg L, Vidula M, et al.

    Current treatment options in cardiovascular medicine 2021; (23(10)) doi:10.1007/s11936-021-00943-0.

    PMID: 35082480
  4. 4

    Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

    Dominguez F, Zorio E, Jimenez-Jaimez J, et al.

    Heart rhythm 2020; (17(6)):945-954 doi:10.1016/j.hrthm.2020.01.035.

    PMID: 32062046
  5. 5

    Arrhythmogenic Cardiomyopathy and Sports Activity.

    Zorzi A, Cipriani A, Mattesi G, et al.

    Journal of cardiovascular translational research 2020; (13(3)):274-283 doi:10.1007/s12265-020-09995-2.

    PMID: 32300932
  6. 6

    Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.

    Rolland T, Badenco N, Maupain C, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2022; (24(2)):278-284 doi:10.1093/europace/euab182.

    PMID: 34459901
  7. 7

    Heterozygous desmoplakin (DSP) variants presenting with early onset cardiomyopathy and refractory ventricular tachycardia.

    Mathavan A, Krekora U, Belaunzaran Dominguez M, Mathavan A

    BMJ case reports 2024; (17(2)) doi:10.1136/bcr-2023-259308.

    PMID: 38383124
  8. 8

    Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.

    Jordà P, Bosman LP, Gasperetti A, et al.

    European heart journal 2022; (43(32)):3041-3052 doi:10.1093/eurheartj/ehac289.

    PMID: 35766180
  9. 9

    Predicting Sudden Cardiac Death in Genetic Heart Disease.

    Cadrin-Tourigny J, Tadros R

    The Canadian journal of cardiology 2022; (38(4)):479-490 doi:10.1016/j.cjca.2022.01.025.

    PMID: 35108574
  10. 10

    Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy?

    Kukavica D, Trancuccio A, Arnò C, et al.

    Minerva cardiology and angiology 2022; (70(2)):217-237 doi:10.23736/S2724-5683.21.05804-X.

    PMID: 34338490
  11. 11

    Prevalence and cardiac phenotype of patients with a phospholamban mutation.

    Hof IE, van der Heijden JF, Kranias EG, et al.

    Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2019; (27(2)):64-69 doi:10.1007/s12471-018-1211-4.

    PMID: 30547415
  12. 12

    Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies.

    Bariani R, Rigato I, Celeghin R, et al.

    Journal of the American College of Cardiology 2024; (83(8)):797-807 doi:10.1016/j.jacc.2023.12.015.

    PMID: 38383094
  13. 13

    Endo-epicardial ablation vs endocardial ablation for the management of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.

    Romero J, Patel K, Briceno D, et al.

    Journal of cardiovascular electrophysiology 2020; (31(8)):2022-2031 doi:10.1111/jce.14593.

    PMID: 32478430
  14. 14

    Arrhythmogenic right ventricular cardiomyopathy: diverse substrate characteristics and ablation outcome.

    Cheng WH, Chung FP, Lin YJ, et al.

    Reviews in cardiovascular medicine 2021; (22(4)):1295-1309 doi:10.31083/j.rcm2204136.

    PMID: 34957771
  15. 15

    Endocardial-Epicardial Catheter Ablation Versus Endocardial Catheter Ablation Alone for Ventricular Arrhythmia in Patients With Structural Heart Disease (Meta-Analysis of Reconstructed Time-to-Event Data).

    Shaheen N, Shaheen A, Elmasry M, Nashwan AJ

    The American journal of cardiology 2023; (201()):185-192 doi:10.1016/j.amjcard.2023.05.068.

    PMID: 37385173
  16. 16

    Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).

    Romero J, Grushko M, Briceño DF, et al.

    Current cardiology reports 2017; (19(9)):82 doi:10.1007/s11886-017-0893-3.

    PMID: 28779285
  17. 17

    Catheter ablation of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy.

    Laredo M, Oliveira Da Silva L, Extramiana F, et al.

    Heart rhythm 2020; (17(1)):41-48 doi:10.1016/j.hrthm.2019.06.022.

    PMID: 31284048

This information is for educational purposes only and does not replace professional medical advice. Always consult your cardiologist or electrophysiologist about your specific ACM treatment plan and exercise restrictions.

Guide contents Inherited arrhythmogenic cardiomyopathy
Patient Resources Research & Literature
04 The Genetics of ACM 06 Living with ACM